Poly Medicure Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 3.50 per equity share.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.2 pts less than Nifty Smallcap 250 and 5.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure Limited's Board meeting on May 25, 2026 approved the following: (1) Audited standalone revenue of Rs. 53,451.14 lakhs for FY26 (up from Rs. 49,365.55 lakhs in FY25); consolidated revenue of Rs. 55,226.79 lakhs; standalone net profit of Rs. 33,598.49 lakhs vs Rs. 33,133.47 lakhs in prior year; standalone EPS of Rs. 33.15 per share. (2) Recommended final dividend of Rs. 3.50 per equity share (70% payout on Rs. 5 face value) for FY25-26, subject to shareholder approval. (3) Re-appointed PricewaterhouseCoopers Services LLP and Oswal Sunil & Co. as internal auditors for FY26-27. Additionally, the company completed two acquisitions during the year: 90% economic rights in Pendracare Group (Netherlands) and 100% in Medistream SA (Citieffe Group, Switzerland), plus acquired Himalayan Mineral Water Private Limited under IBC resolution plan for Rs. 3,316 lakhs.
The recommended dividend of Rs. 3.50 per share maintains a consistent payout policy, reflecting stable earnings growth. The acquisitions in Europe expand the company's global footprint in medical devices. The unqualified auditors' opinion adds credibility to the financial results.